Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cannara Biotech Inc
(OP:
LOVFF
)
0.9125
UNCHANGED
Last Price
Updated: 9:30 AM EDT, Apr 15, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cannara Biotech Inc
< Previous
1
2
Next >
Cannara Biotech Q1 Revenue Grows 57% YoY To $7.7M, What About Adjusted EBITDA?
January 23, 2023
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA: 8CB) released its fiscal first quarter 2023 financial results for the three-month period ended November 30, 2022, revealing revenue of CA$10.3...
Via
Benzinga
Cannara Biotech Q4 Revenue Grows 84% YoY To $8.9M
November 28, 2022
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB) released its fiscal fourth quarter and fiscal year 2022 financial results for the three-month and full year periods ended August 31, 2022,...
Via
Benzinga
Cannara Biotech Enters Into The British Columbia Cannabis Market And Launches New Products
September 20, 2022
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB), a Quebec-based, vertically integrated producer of cannabis and derivative product offerings, entered into the British Columbia (BC) market.
Via
Benzinga
Cannara Biotech Signs An Exclusive Brand Partnership With Exotic Genetix In Canada
August 03, 2022
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA: 8CB) entered into an exclusive brand partnership with Exotic Genetix Ltd.
Via
Benzinga
Cannara Biotech Revenue Grows 41% YoY, Here Are The Details
July 27, 2022
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB) fiscal Q3 2022 revenue was $10.1 million, a 36% increase from the previous quarter and a 41% increase compared to Q3 2021.
Via
Benzinga
Cannara Biotech Closes $50 Million Credit Facility Led By BMO Commercial Banking
June 02, 2022
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB) has closed on a $50M credit facility led by BMO Commercial Banking.
Via
Benzinga
Cannara Biotech Revenues Grew 229% To $7.4M In Q2 2022 YoY
April 27, 2022
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA: 8CB) released its fiscal second quarter 2022 financial and operating results for the three and six-month periods ended February 28, 2022.
Via
Benzinga
The Week In Cannabis: Isiah Thomas, Tilray, The DEA, Ohio, Mexico And More
December 10, 2021
Below is a recap of the main news related to the cannabis industry and markets for the week of December 6, 2021.
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Cannara Biotech Shares Surge On 983% QoQ Revenue Growth, Positive Adjusted EBITDA
December 09, 2021
Vertically integrated cannabis company Cannara Biotech Inc. (TSXV:
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Tilray Best Performer Among Canadian Cannabis LPs, Stocks Plunge Nearly 10% In July
August 02, 2021
Canadian cannabis stocks took a beating In July, with the Canadian Cannabis LP Index posting a 9.8% loss while continuing the decl...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Cannara Biotech Cannabis Co. Slightly Beats Estimates, Posts $7.2M In Q3 2021 Revenue
July 29, 2021
Vertically integrated cannabis company Cannara Biotech Inc. (TSXV:
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
The Week In Cannabis: Justice Clarence Thomas, Mexico's Decriminalization, Apple's Policy Changes, Tilray And More
July 02, 2021
Below is a recap of the main news related to the cannabis industry and markets for the week of June 28, 2021. Justice Thomas&nbs...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Cannara Biotech Cannabis Co. Expects To Post $7.1M In Q3 Revenue After Successful Market Launch In Quebec
June 28, 2021
Cannara Biotech Inc. (TSXV:LOVE) (OTCQB:
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.